Atlas Trials

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Clinical trial NCT01797120 · COMPLETED

Trial details

NCT number
NCT01797120
Sponsor
PrECOG, LLC.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2013-05-31
Primary completion
2017-03-22
Enrollment
131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.